A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

被引：0
|
作者：
Angelo Camporeale
David Kudrow
Ryan Sides
Shufang Wang
Annelies Van Dycke
Katherine J. Selzler
Virginia L. Stauffer
机构：
[1] Eli Lilly Italia,Neurology Department
[2] California Medical Clinic for Headache,undefined
[3] UCLA David Geffen School of Medicine,undefined
[4] Eli Lilly and Company Corporate Center,undefined
[5] AZ Sint-Jan Brugge,undefined
来源：
BMC Neurology | / 18卷
关键词：
Migraine; Headache; Galcanezumab; CGRP;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Camporeale, Angelo
    Kudrow, David
    Sides, Ryan
    Wang, Shufang
    Van Dycke, Annelies
    Selzler, Katherine J.
    Stauffer, Virginia L.
    [J]. BMC NEUROLOGY, 2018, 18
  • [2] A long-term open-label safety study of galcanezumab in Japanese patients with migraine
    Hirata, Koichi
    Takeshima, Takao
    Sakai, Fumihiko
    Tatsuoka, Yoshihisa
    Suzuki, Norihiro
    Igarashi, Hisaka
    Nakamura, Tomomi
    Ozeki, Akichika
    Yamazaki, Hiroyoshi
    Skljarevski, Vladimir
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 721 - 733
  • [3] A Phase 3, Long-Term, Open-Label Safety Study of Self-Administered Galcanezumab Injections in Patients with Migraine
    Stauffer, Virginia L.
    Sides, Ryan
    Camporeale, Angelo
    Skljarevski, Vladimir
    Ahl, Jonna
    Aurora, Sheena K.
    [J]. CEPHALALGIA, 2017, 37 : 330 - 331
  • [4] Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache
    Riesenberg, Robert
    Gaul, Charly
    Stroud, Chad E.
    Dong, Yan
    Bangs, Mark E.
    Wenzel, Richard
    Martinez, James M.
    Oakes, Tina Myers
    [J]. CEPHALALGIA, 2022, 42 (11-12) : 1225 - 1235
  • [5] Patient Functioning and Disability among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
    McAllister, Peter
    Ford, Janet H.
    Stauffer, Virginia L.
    Sexson, Matthew
    Ayer, David
    Wang, Shufang
    [J]. NEUROLOGY, 2020, 94 (15)
  • [6] Patient Functioning and Disability Among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study
    McAllister, P.
    Ford, J.
    Stauffer, V
    Sexson, M.
    Ayer, D.
    Wang, S.
    [J]. HEADACHE, 2019, 59 : 99 - 100
  • [7] Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
    Ford, Janet H.
    Stauffer, Virginia L.
    McAllister, Peter
    Akkala, Sreelatha
    Sexson, Matthew
    Ayer, David W.
    Wang, Shufang
    [J]. QUALITY OF LIFE RESEARCH, 2021, 30 (02) : 455 - 464
  • [8] Correction to: Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study
    Janet H. Ford
    Virginia L. Stauffer
    Peter McAllister
    Sreelatha Akkala
    Matthew Sexson
    David W. Ayer
    Shufang Wang
    [J]. Quality of Life Research, 2021, 30 : 465 - 466
  • [9] Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
    Pozo-Rosich, Patricia
    Detke, Holland C.
    Wang, Shufang
    Dolezil, David
    Li, Lily Q.
    Aurora, Sheena K.
    Reuter, Uwe
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (05) : 731 - 742
  • [10] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Jiying Zhou
    Lianmei Zhong
    Debashish Chowdhury
    Kirill Skorobogatykh
    Guogang Luo
    Xiaosu Yang
    Mingjie Zhang
    Lingli Sun
    Hui Liu
    Chenxi Qian
    Shengyuan Yu
    [J]. The Journal of Headache and Pain, 24
12345